Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Optinose Inc (OPTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 914,140
  • Shares Outstanding, K 38,010
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,900 K
  • 36-Month Beta N/A
  • Price/Sales 1,043.05
  • Price/Cash Flow N/A
  • Price/Book 7.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.20 +17.82%
on 04/27/18
25.74 -7.54%
on 05/15/18
+3.32 (+16.21%)
since 04/25/18
3-Month
16.50 +44.24%
on 03/13/18
25.74 -7.54%
on 05/15/18
+6.49 (+37.49%)
since 02/23/18
52-Week
15.01 +58.56%
on 11/14/17
25.74 -7.54%
on 05/15/18
+4.80 (+25.26%)
since 10/13/17

Most Recent Stories

More News
New Study of Option Care Data Suggests Improved Survival for Heart Failure Patients Receiving Home Infusion of Inotropic Therapy When Coupled with Guideline-Directed Medical Therapy

Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of a large study recently...

OPTN : 23.80 (-1.04%)
OptiNose, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2018 / OptiNose, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 8:00 AM Eastern Time.

OPTN : 23.80 (-1.04%)
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights

Optinose confirms retail pharmacy availability of XHANCE commenced in early April

OPTN : 23.80 (-1.04%)
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first...

OPTN : 23.80 (-1.04%)
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President/COO Ramy Mahmoud,...

OPTN : 23.80 (-1.04%)
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was named the Emerging Company of the Year...

OPTN : 23.80 (-1.04%)
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights

Optinose expects early April availability of XHANCE in retail pharmacies

OPTN : 23.80 (-1.04%)
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth...

OPTN : 23.80 (-1.04%)
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic...

OPTN : 23.80 (-1.04%)
Optinose names Sandra L. Helton as Director and Chairperson of the Company's Audit Committee

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Sandra L. Helton as...

OPTN : 23.80 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade OPTN with:

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

2nd Resistance Point 24.54
1st Resistance Point 24.17
Last Price 23.80
1st Support Level 23.35
2nd Support Level 22.90

See More

52-Week High 25.74
Last Price 23.80
Fibonacci 61.8% 21.64
Fibonacci 50% 20.38
Fibonacci 38.2% 19.11
52-Week Low 15.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar